



# Small-molecule inhibitors of macrophage migration inhibitory factor (MIF) as an emerging class of therapeutics for immune disorders

Tjie Kok<sup>1,2</sup>, Anna A. Wasiel<sup>1</sup>, Robbert H. Cool<sup>1</sup>, Barbro N. Melgert<sup>3,4</sup>, Gerrit J. Poelarends<sup>1</sup> and Frank J. Dekker<sup>1</sup>

<sup>1</sup> Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands

<sup>2</sup> Faculty of Biotechnology, University of Surabaya, Jalan Raya Kalirungkt Surabaya, 60292, Indonesia

<sup>3</sup> Department of Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands

<sup>4</sup> GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

**Macrophage migration inhibitory factor (MIF) is an important cytokine for which an increasing number of functions is being described in the pathogenesis of inflammation and cancer. Nevertheless, the availability of potent and druglike MIF inhibitors that are well-characterized in relevant disease models remains limited. Development of highly potent and selective small-molecule MIF inhibitors and validation of their use in relevant disease models will advance drug discovery. In this review, we provide an overview of recent advances in the identification of MIF as a pharmacological target in the pathogenesis of inflammatory diseases and cancer. We also give an overview of the current developments in the discovery and design of small-molecule MIF inhibitors and define future aims in this field.**

## Introduction

Despite its discovery over 50 years ago in 1966 [1,2], the functions of the cytokine macrophage migration inhibitory factor (MIF) have still not been fully elucidated. Initially, MIF was identified as a T-cell-derived mediator that inhibits random movement of macrophages. Its activity was found to correlate with delayed-type hypersensitivity reactions, a prominent feature of several chronic diseases in humans [2]. In addition, MIF is released at sites of infection, causing macrophages to concentrate and carry out antigen processing and phagocytosis [3]. Today, MIF is recognized as a crucial player in innate immune responses and has a role in multiple diseases [4,5]. Therefore, the development of small-molecule MIF inhibitors that interfere with its functions is quickly gaining importance.

The human MIF gene was cloned and expressed for the first time in 1989 [6]. MIF is a relatively small protein that consists of 114 amino acids and has a molecular mass of 12 345 Da. Structural analysis of MIF revealed its striking similarities to bacterial

enzymes from the tautomerase superfamily. Searching the human genome indicated that D-dopachrome tautomerase (D-DT) is another gene with marked homology to MIF. Owing to this similarity, D-DT is also referred to as MIF2 and an overlapping functional spectrum for MIF and D-DT has been suggested [7]. This should be considered in the evaluation of MIF cytokine activities and in the development of small-molecule MIF modulators.

MIF, a member of the tautomerase superfamily [8], is found across various organisms including bacteria, mice, plants, protozoa, helminths, molluscs, arthropods and fish [9–11]. These tautomerase superfamily members have similar enzyme activity involving an amino-acid-terminal proline that acts as a general base in keto-enol tautomerisation reactions of  $\alpha$ -keto-carboxylates. In addition to its cytokine activity, MIF harbors keto-enol tautomerase and low-level dehalogenase activity, providing a functional link to other members of the tautomerase superfamily [10]. MIF is a homotrimeric protein in which three monomers associate to form a symmetrical trimer (Fig. 1a). Each MIF trimer has three tautomerase active sites at the interfaces of the monomer subunits. Characteristic for this family, MIF has an N-terminal

Corresponding author: Dekker, F.J. (f.j.dekker@rug.nl)




FIGURE 1

**(a)** Crystal structure of macrophage migration inhibitory factor (MIF), showing that three monomers associate to form a symmetrical homotrimer (PDB 1CA7). **(b)** MIF catalyzes the tautomerisation of  $\alpha$ -keto-carboxylates. **(c)** Diseases for which a role of MIF has been described.

proline (Pro-1), which is located within a hydrophobic pocket [12]. The residue Pro-1 was shown to be conserved between MIF and its bacterial homologs. Moreover, other invariant residues were identified as being clustered around the N-terminal proline. The evolutionary preservation of this region suggests its importance in the biological function of MIF [13]. Despite the lack of a known physiological substrate, it was shown that *D*-dopachrome (a stereoisomer of naturally occurring *L*-dopachrome), phenylpyruvate and *p*-hydroxyphenylpyruvate are accepted as substrates by MIF (Fig. 1b) [14,15]. A crystal structure of MIF in complex with *p*-hydroxyphenylpyruvate demonstrated that Pro-1 functions as a catalytic base in the tautomerase reaction [16]. It is well recognized that the currently defined substrates of MIF either do not exist naturally *in vivo* or do not exist at significant concentrations required for biological activity [17]. Nevertheless, small-molecule modulators of MIF tautomerase activity could have an impact on MIF cytokine activity owing to modulation of its conformation and/or ability to interact with other proteins.

Although MIF tautomerase activity might not be directly linked to its cytokine activity, it provides an opportunity for efficient screening of compound collections that could provide molecules that interfere with MIF cytokine activity. One of the best known targets to mediate MIF cytokine activity upon binding is the cluster of differentiation 74 (CD74) receptor [18]. Interestingly, recent findings demonstrate that MIF binding to CD74 occurs in

the vicinity of the MIF tautomerase active site, which supports the idea that MIF tautomerase inhibitors could have potential to interfere with MIF cytokine function [19]. In this perspective, robust assays to test the ability of MIF tautomerase inhibitors to interfere with MIF cytokine functions *in vitro* and *in vivo* are highly important.

Functional cytokine roles of MIF and *D*-DT have been described in innate and adaptive immune responses [7,13]. It has been shown that MIF stimulates the production of proinflammatory mediators such as tumor necrosis factor (TNF) $\alpha$ , interferon (IFN) $\gamma$ , interleukin (IL)-1 $\beta$ , IL-2, IL-6 and IL-8 and other effector cytokines [13]. The MIF-CD74 interaction is well known to initiate subsequent signaling cascades leading to cellular responses [18]. The biological functions of the CD74 receptor in immune diseases have recently been reviewed by Su *et al.* [20]. With respect to CD74 binding it is interesting to note that a difference has been reported between MIF and *D*-DT in a study by Merk *et al.* [21]. The same study indicates that MIF has a steeper dose:response ratio for macrophage migration inhibition and glucocorticoid overriding. This suggests an immune downregulatory role for *D*-DT in the presence of MIF. By contrast, a recent study demonstrated that MIF and *D*-DT are both connected to disease progression of multiple sclerosis subjects [22]. This study and other studies as reviewed by Merk *et al.* [7] and O'Reilly *et al.* [23] indicate an overlapping activity spectrum for both cytokines.

Apart from the CD74 receptor, MIF can also bind to chemokine receptors such as CXCR2, CXCR4 and CXCR7 to induce inflammatory and immune cell chemotaxis [24,25]. Given the pro-inflammatory activities, MIF is implicated in acute and chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, sepsis, diabetes, atherosclerosis and cardiovascular diseases [13]. Many studies have investigated MIF as a biomarker for various diseases that have an inflammatory component, including systemic infections and sepsis, cancer, autoimmune diseases and different metabolic disorders, suggesting its important role in these diseases [26]. It should also be noted that MIF has been demonstrated to be posttranslationally modified and that these modifications affect its biological functions [27]. MIF, but not D-DT, has a CXXC motif that can be oxidized to an intramolecular disulfide bond. Oxidized MIF has also been proposed as a biomarker for different diseases [28]. Other studies indicate that oxidized MIF is the disease-related conformational isoform that could be employed for diagnosis and therapy [29,30]. It is to be expected that MIF redox behavior interferes with

binding of small-molecule inhibitors. However, little is known about the structural consequences of these modifications in relation to inhibitor binding. Therefore, this represents an interesting and novel line of investigation.

Despite extensive studies on the functional role of MIF in multiple disease models, the identification and validation of the functional consequences of small-molecule MIF tautomerase inhibitors is still at an early stage. The effects of such inhibitors have been investigated using the long-known standard MIF antagonist ISO-1 (Table 1) in *in vitro* assays and animal models [31]. Research on MIF antagonists is still at the preclinical stage and data on human disease are still observational [32], which indicates a need for further validation of MIF as a drug target. In this review, we aim to provide an overview of recent advances in the identification of MIF as a pharmacological target in the pathogenesis of inflammatory diseases and cancer (Fig. 1c). Based on that, we will provide an overview of the current developments in the discovery and design of small-molecule MIF inhibitors and define future goals in this field.

TABLE 1

**MIF inhibitors with a phenol functionality as the key structural element that presumably binds to the active-site residue Asn-97 of MIF**

Class	Compound	Structure	Activity ( $\mu\text{M}$ ) Refs
Chromen-4-one	Orita-13		$K_i = 0.04$ [51] (TA), $K_i = 17$ [61] (TA), $K_i = 13\text{--}22$ [52] (TA)
Isoxazoline	ISO-1		$\text{IC}_{50} = 7$ [53] (TA), $\text{IC}_{50} = 24$ [52] (TA); Max. 40% inhibition [54] (BA)
	Alam-4b		$\text{IC}_{50} = 7.3$ [58] (TA)
	ISO-66		$\text{IC}_{50} = 1.5$ [59] (TA)
1,2,3-Triazole	Jorgensen-3g		$\text{IC}_{50} = 0.75$ [60] (TA); $\text{IC}_{50} = 0.9$ [60] (BA)
	Jorgensen-3h		$\text{IC}_{50} = 1$ [60] (BA)
	Dziedzic-3bb (Cisneros-3i)		Dziedzic-3bb: $K_i = 0.057$ [61] (TA) Cisneros-3i: $K_i = 0.057$ [62] (TA); $K_d = 0.071$ [62] (BA)
Cisneros-3j		$K_i = 0.034$ [62] (TA); $K_d = 0.063$ [62] (BA)	

Abbreviations: TA, tautomerase assay; BA, binding assay MIF-CD74.












## The role of MIF in pathogenesis of inflammatory diseases

Acute inflammation is a protective, beneficial and self-limiting process during innate immune responses, but chronic inflammation is maladaptive and can result in tissue injury and dysfunction. For instance, some studies have shown that MIF plays an important part in the pathology of bladder inflammation. In bladder tissue substance P, an important inflammatory mediator, increases the levels of MIF. The important role of MIF was subsequently shown by administration of an anti-MIF antibody that could decrease substance-P-induced inflammatory

changes in the bladder [33]. MIF was also shown to play a part in worsening of lung inflammation. High levels of MIF were reported to be detrimental for survival in a mouse model of pneumococcal pneumonia. Treatment of mice with a small-molecule inhibitor of MIF, designated MIF098 (Alissa-5) (Table 2), improved survival by reducing inflammatory responses [34]. In addition, higher MIF levels were produced by alveolar macrophages in a mouse model for COPD as compared with those from healthy mice, and inhibition of MIF function by ISO-1 could block the corticosteroid-insensitive lung inflammation [35].

TABLE 2

### Covalent MIF inhibitors and MIF inhibitors with other structures

Class	Compound	Structure	Activity ( $\mu\text{M}$ ) Refs
Phenyl-pyrimidine	4-IPP		$\text{IC}_{50} = 0.2\text{--}0.5$ [63] (TA)
Isothiocyanate	BITC		$\text{IC}_{50} = 0.79$ [65] (TA)
Benzoxazinone	NVS-2		$\text{IC}_{50} = 0.020$ [69] (TA); $K_i = 0.027$ [52] (TA); $K_d = 0.055$ [52] (BA)
Benzoxazol-2-one	MIF098 (Alissa-5)		$\text{IC}_{50} = 0.01$ [70] (TA)
Pyrimidazole	K664-1		$\text{IC}_{50} = 0.11$ [73] (TA); $K_i = 45$ [52] (TA), $K_i = 0.16$ [72] (TA)
Chromene	T-614		$\text{IC}_{50} = 6.81$ [72] (TA)
	Kok-10		$\text{IC}_{50} = 18$ [74] (TA)
	Kok-17		$\text{IC}_{50} = 6.2$ [74] (TA)
Isoxazoline	CPSI-2705		2–10-fold more potent than ISO-1 [44] (TA)
	CPSI-1306		100-fold more potent than ISO-1 [44] (TA)
Isocoumarin	SCD-19		100% inhibition at concentration of 100 $\mu\text{M}$ [46] (TA)

Abbreviations: TA, tautomerase assay; BA, binding assay MIF-CD74.

MIF also acts as an essential mediator of host immunity against various bacterial infections; however, its persistent or recurrent expression during chronic inflammatory disease stages can lead to loss of function and mortality. The involvement of MIF in the enhancement of biofilm formation by *Pseudomonas aeruginosa* was shown by the use of SCD-19, a small-molecule inhibitor targeting MIF tautomerase activity. Application of this inhibitor resulted in lower bacterial burden in a mouse model of this infection as compared with untreated mice [36]. As another example, MIF promotor polymorphisms resulting in high MIF levels in cerebrospinal fluid of patients with streptococcal meningitis correlated with systemic complications and death [37]. Moreover, the authors of this study showed a reduction in bacterial load in a mouse model of pneumococcal pneumonia and sepsis after treatment with an anti-MIF antibody. From these studies it becomes clear that MIF plays a part in biofilm formation and mortality during bacterial infections, and it provides initial evidence that targeting MIF with small-molecule inhibitors has potential to interfere with such pathological conditions.

A relationship of MIF with autoimmune inflammatory disease has been observed in experimental autoimmune myocarditis. Early treatment of this disease with an anti-MIF antibody markedly delayed the onset of, and significantly reduced the severity of, this disease in rats [38]. The importance of MIF in the autoimmune inflammatory process has also been demonstrated for rheumatoid arthritis. It was observed that treatment with an anti-MIF antibody before immunization with type II collagen leads to delayed onset of arthritis in a mouse model of collagen-induced arthritis [39]. Altogether, these studies indicated that MIF correlates with disease severity in autoimmune inflammatory diseases and that treatment with anti-MIF antibodies has beneficial effects.

### The role of MIF in cancer pathogenesis

Inflammation and immunity have key roles in the onset and progression of cancer. Persistent or recurrent inflammation is related to development of cancer. By contrast, anticancer immune responses counteract the development and progression of cancer. From this perspective, the functional output of MIF as a key cytokine of the immune system can be connected to various aspects of oncology [40]. High serum levels of MIF are seen in cancer patients' tissues and MIF has consequently been proposed as a biomarker. In addition, high MIF levels correlate with poor prognosis in various carcinomas. Besides being involved in angiogenesis and thus indirectly in promoting tumour growth, the interaction of MIF with its receptors has been shown to initiate cancer-promoting signal transduction pathways. For example, binding of MIF to CD74 can lead to stimulation of the ERK1/2 but also PI3K/AKT pathways and binding of MIF to the CXCR4 receptor was suggested to induce metastases [41].

Involvement of MIF in the development of prostate cancer was shown by studies with an androgen-independent prostate cancer cell line. In these studies, inhibition of MIF by ISO-1, anti-MIF antibody or MIF siRNA resulted in decreased cell proliferation. ISO-1 significantly decreased tumor volume and tumor angiogenesis [42]. In another study with a prostate cancer cell line, treatment with anti-MIF antibodies was reported to reduce cell growth and, in a xenograft mouse model of prostate cancer, anti-MIF antibodies were shown to limit tumor growth [43]. The involvement of

MIF in the development of bladder cancer has also been described. MIF was reported to promote *in vitro* and *in vivo* bladder cancer progression via increasing cell proliferation and angiogenesis. The orally available MIF inhibitors CPSI-2705 and CPSI-1306 (Table 2) have been shown to effectively decrease the growth and progression of bladder cancer *in vivo* [44].

A study on the role of MIF in the development of colon cancer in patients reported a positive correlation between MIF serum concentrations and colorectal cancer severity [45], thus indicating a potential use of MIF as a biomarker. The same study demonstrated in a mouse model with colon carcinoma cell transplants that treatment with MIF inhibitor ISO-1 or anti-MIF antibodies resulted in a significant reduction of the tumor burden, thus indicating a potential use of MIF-directed therapeutics in cancer. Furthermore, MIF has been indicated to be involved in the progression of lung cancer. Blocking the hydrophobic pocket that harbours MIF tautomerase activity, by a small-molecule inhibitor of the isocoumarin class, SCD-19 (Table 2), which significantly attenuated lung cancer growth [46]. Taken together, these studies demonstrate a positive correlation between MIF and the progression of cancer. Application of small-molecule MIF inhibitors or anti-MIF antibodies attenuated cancer growth, thus indicating the potential of anti-MIF therapeutics in cancer [47–49].

### Small-molecule inhibitors of MIF

Because of the essential involvement of MIF in the progression of numerous disorders with an inflammatory component, it is not surprising that attempts were made to find MIF-directed therapeutics. One line of development is the application of biologicals, such as anti-MIF antibodies, as novel therapeutics. This approach has been used in many proof-of-concept studies [33,38,39,42,43,45]. One clinical trial with an anti-MIF antibody has been reported, however no results have been revealed yet [50]. The other line of development is to generate MIF-binding small molecules with the aim to interfere with MIF functions. To develop MIF inhibitors, many studies resort to evaluating interference with MIF tautomerase activity. In this perspective, the evaluation of MIF tautomerase inhibitors for their interference with MIF cytokine functions in relevant disease models is highly important. Compared with biologicals, small-molecule MIF inhibitors offer advantages such as lower manufacturing costs, nonimmunogenic reactions and the possibility of oral administration. Therefore, this route of exploration gained tremendous interest. Here, we summarize the currently identified MIF tautomerase inhibitors and discuss their SAR. Inhibitors containing a chromen-4-one scaffold were identified in 2001 and their  $K_i$  values range between 0.04 and 7.4  $\mu\text{M}$ . The most potent compound of this class is Orita-13 with a  $K_i$  of 0.04  $\mu\text{M}$  [51]. However, a later investigation reported  $K_i$  values in the range of 13–22  $\mu\text{M}$  for Orita-13 [52]. The phenol functionality in Orita-13 is also found in the MIF tautomerase substrates D-dopachrome and *p*-hydroxyphenylpyruvate and proved to be a successful design motif for MIF inhibitors (Table 1).

### Isoxazolines as MIF inhibitors

The most frequently used reference inhibitor for MIF tautomerase activity is ISO-1, which was discovered in 2002. This inhibitor of the isoxazoline class was reported to inhibit MIF tautomerase activity in a dose-dependent manner. It binds at the same position

as the substrate *p*-hydroxyphenylpyruvate with an  $IC_{50}$  of about 7  $\mu\text{M}$  [53]. A later study described a  $K_i$  of 24  $\mu\text{M}$  for inhibition of MIF tautomerase activity [52]. A MIF-CD74 binding study reported a maximum of 40% inhibition at 10  $\mu\text{M}$  (Table 1) [54]. Further studies showed that inhibition of MIF by ISO-1 in a mouse model significantly reduced prostate cancer [42] and colon cancer [45] and blocked melanoma cell growth [55]. Another study in a mouse model showed that this MIF inhibitor blocks corticosteroid-insensitive lung inflammation [35]. In addition, ISO-1 was also reported to inhibit MIF activity in a mouse model of type 1 diabetes and to result in the delayed onset of this disease [56]. Altogether, ISO-1 is a valuable compound that is widely used as a reference inhibitor in the initial validation of small-molecule MIF tautomerase inhibitors as potential therapeutics in diseases with an inflammatory component.

Another small-molecule MIF tautomerase inhibitor with an isoxazoline scaffold is CPSI-1306 (Table 2). This inhibitor lacks the characteristic phenol functionality, which is advantageous for applications *in vivo*. Phenol functionalities are generally considered to be nondruglike because they are prone to Phase II bioconjugation reactions, thus resulting in quick inactivation and excretion in *in vivo* experiments. Oral administration of this inhibitor resulted in less severe symptoms in a mouse model for multiple sclerosis as compared with untreated mice [57]. Further small molecules with the same scaffold were synthesized and evaluated for MIF-inhibitory activity. The  $IC_{50}$  of the most active compound, Alam-4b (Table 1), was 7.3  $\mu\text{M}$  in a MIF tautomerase assay and this compound was shown to be nontoxic in a cell viability assay [58]. Subsequently, in 2014, another small-molecule inhibitor from the isoxazoline class, ISO-66 (Table 1), was reported. Its  $IC_{50}$  in the MIF tautomerase assay was 1.5  $\mu\text{M}$  and long-term administration of ISO-66 in a mouse model of colon cancer or melanoma was shown to be nontoxic and to decrease tumor burden significantly [59]. Thus, studies on MIF inhibitors with an isoxazoline scaffold demonstrate that the development and application of small-molecule MIF inhibitors has the potential to provide novel therapeutics.

### 1,2,3-Triazoles as MIF inhibitors

In 2010, 1,2,3-triazole derivatives were reported as inhibitors of MIF. The most potent compounds, Jorgensen-3g and Jorgensen-3h (Table 1), showed  $IC_{50}$  values of  $\sim 1 \mu\text{M}$  for MIF tautomerase activity and MIF-CD74 binding [60]. Subsequently, in 2015, improvements were made by the synthesis of several optimized biaryltriazoles. This provided potent compounds with a phenolic hydroxyl group that binds to the MIF tautomerase active site. Nevertheless, some compounds had limited water solubility. The activity of this class of compounds was further improved by the addition of a fluorine atom adjacent to the phenolic hydroxyl group to enhance the H-bond interaction with residue Asn-97 of MIF. This yielded the most potent compound, Dziedzic-3bb (Table 1), having a  $K_i$  value of 0.057  $\mu\text{M}$  and a solubility that is in the normal range for orally available drugs [61]. The synthesis of fluorescently labeled MIF inhibitors with a biaryltriazole scaffold was described in 2016. These inhibitors were used in a fluorescence polarization assay to assess the direct binding of inhibitors to the active site of MIF. The two most potent inhibitors, denoted Cisneros-3i and Cisneros-3j, were reported to have  $K_i$  values of 0.057

and 0.034  $\mu\text{M}$  in the tautomerase assay and  $K_d$  values of 0.071 and 0.063  $\mu\text{M}$  in the fluorescence-polarization-based binding assay (Table 1) [62].

### Covalent MIF inhibitors

The specific reactivity of the proline in the MIF active site provides opportunities to develop covalent inhibitors. In 2008, a compound of the phenyl-pyrimidine class, 4-IPP (Table 2), was reported to inactivate the MIF catalytic function by dehalogenation and formation of a covalent bond between C-4 of pyrimidine and the N-terminal nitrogen of Pro-1 in the MIF tautomerase active site. This compound also interferes with the biological functions of MIF as it was reported to irreversibly inhibit lung adenocarcinoma cell migration and anchorage-independent growth [63]. Later on, it was described that 4-IPP inhibits the growth of thyroid cancer cells by inducing apoptosis and mitotic cell death [64]. In 2009, isothiocyanates were discovered as irreversible MIF tautomerase inhibitors. The isothiocyanate BITC (Table 2) was shown to covalently modify the Pro-1 residue in the MIF active site. This drastically alters the MIF tertiary structure and results in loss of its tautomerase activity and in inhibition of MIF binding to CD74 [65].

Woodward's reagent K is a classical heterocyclic electrophile with a specific reactivity [66,67]. Taking advantage of the specific reactivity of Woodward's reagent K, covalent MIF inhibitors were developed. These inhibitors were shown to react with the active site Pro-1 of MIF and were applied for covalent labeling of MIF which proved to be selective. The covalent inhibitors were used as probes for labeling and imaging of MIF activities in living cells [68]. These examples demonstrate that it is possible to develop covalent active-site-directed inhibitors of MIF that bind with a reasonable level of selectivity. Such inhibitors have great potential for labeling and imaging of enzyme activity *in vitro* and *in vivo*. In contrast to their application in imaging, covalent inhibitors are not preferred in pharmacotherapy owing to concerns about their off-target effects.

### Other types of MIF inhibitors

Apart from the isoxazolines and 1,2,3-triazoles, other types of reversible MIF inhibitors were also developed. In 2006, MIF inhibitors with a benzoxazinone scaffold were described and patented. The most potent compound, NVS-2, was reported to have an  $IC_{50}$  of 0.020  $\mu\text{M}$  (Table 2) [69]. A later assay by Cisneros *et al.* reported a similar value for the  $K_i$  of 0.027  $\mu\text{M}$  in the tautomerase assay and a  $K_d$  of 0.055  $\mu\text{M}$  in the fluorescence-polarization-based binding assay [62]. Subsequently, in 2010, substituted benzoxazol-2-ones were discovered as MIF antagonists (Table 2). One potent inhibitor from this class, MIF098 (Alissa-5) showed noncovalent inhibition in the MIF tautomerase assay, with an  $IC_{50}$  of  $\sim 0.010 \mu\text{M}$ . This inhibitor was further reported to attenuate MIF-dependent ERK phosphorylation in human synovial fibroblasts, which demonstrates possible use of MIF inhibition as a therapy in rheumatoid arthritis [70].

In 2012, an allosteric MIF tautomerase inhibitor p425 was identified in an HTS of a library consisting of 230 000 small molecules. However, this compound is a sulfonated azo compound (also known as pontamine sky blue) that has poor druglike properties [71]. Another study, reported for MIF inhibitor K664-1

(Table 2) with a pyrimidazole scaffold an  $IC_{50}$  of 0.16  $\mu M$  in the MIF tautomerase assay [72]. This inhibitor provided protection to  $\beta$  cells from cytokine-triggered apoptosis in a mouse model, which demonstrates its potential for the prevention of diabetes progression [73].

In 2016, compound T-614 (also known as iguratimod) was found to selectively inhibit MIF *in vitro* and *in vivo*. The compound has synergic effects with glucocorticoids to slow disease progression in a mouse model of multiple sclerosis. The  $IC_{50}$  of that compound in the MIF tautomerase assay was 6.81  $\mu M$  (Table 2) [72]. Recently, novel types of MIF inhibitors were discovered using substitution-oriented screening (SOS). Inspired by the known chromen-4-one inhibitor Orita-13, a focused collection of compounds with a chromene scaffold was screened for MIF binding. In this study, inhibitors denoted Kok-10 and Kok-17 (Table 2) provided  $IC_{50}$  values in the low micromolar range (18 and 6.2  $\mu M$ , respectively) in the MIF tautomerase assay. The binding proved to be reversible and the enzyme kinetics suggested no direct interaction of these compounds with the substrate-binding pocket [74].

### Future perspectives of inhibitor development

Altogether it can be concluded that a diverse array of structures can be employed to develop MIF inhibitors that interact with MIF tautomerase activity via direct competition, via allosteric modulation of substrate binding or via covalent binding. These provide valuable starting points to design novel structural motifs that can be employed to interfere with MIF cytokine functions. Inhibitors of the enzymatic activity of MIF should also be evaluated in assays for binding to the cellular receptors such as CD74, CXCR2, CXCR4 and CXCR7 and/or in disease models. Within this context it is important to note that a study by Cisneros *et al.* in 2016 demonstrated that the reported  $IC_{50}$  values of MIF tautomerase inhibitors were often not reproducible [52]. Most inhibitors were shown to be less potent than previously reported. As pointed out, for covalent or slow-tight-binding inhibitors the  $IC_{50}$  values are time dependent. Therefore, it is important to evaluate the reversibility of binding by recovery of enzyme activity in, for example, dilution experiments [75], which is too often neglected. Another complicating factor is the enzyme kinetics of the MIF tautomerase activity for its substrate *p*-hydroxyphenylpyruvate (4-HPP), which provides a sigmoidal curve that cannot be fitted to a simple one-to-one binding model. Thus, the Michaelis–Menten constant  $K_m$  cannot be derived easily and one needs to resort to  $K_{half,app}$  [74] or  $[S]_{0.5}$  [16]. This issue complicates the calculation of the equilibrium constant for inhibition ( $K_i$ ) from  $IC_{50}$  values. Therefore, we argue to include enzyme dilution experiments and enzyme kinetic studies, or direct binding assays, if  $IC_{50}$  values are reported to provide a more complete analysis of MIF binding.

### Concluding remarks

MIF has been described to have a key role in the pathogenesis of inflammatory diseases and cancer. Small-molecule inhibitors of MIF have been developed and used in studies to investigate the biological role of MIF. Inhibitor ISO-1 is widely used as a reference compound for MIF inhibition in mouse models of lung inflammation, prostate cancer, colon cancer, melanoma and diabetes. Other small-molecule inhibitors also provided positive effects in various disease models. Altogether this indicates the potential of MIF inhibitors for development of novel therapeutics for diseases with an inflammatory component.

It is commonly presumed that MIF inhibitors identified in a MIF tautomerase assay have potential to interfere with MIF cytokine functions. Following this hypothesis, several classes of MIF tautomerase inhibitors have been identified. The isoxazolines and the 1,2,3-triazoles are important classes of inhibitors from which potent MIF inhibitors were identified. Also, covalent inhibitors that react with the active site Pro-1 of MIF have been identified and in one case used for activity-based labeling of MIF in living cells. Over time, an increasing number of MIF inhibitors has been described, thus providing more insight in SAR for MIF binding. A complicating factor in the analysis of MIF inhibitors proved to be covalent or slow-tight-binding behavior that results in overestimation of the inhibitor potency. Also, the sigmoidal enzyme kinetics for MIF tautomerase activity complicates analysis of MIF binding. We argue that anticipation of these issues is needed for successful further development of the field. Ultimately, the identification of potent MIF inhibitors with favorable properties for drug discovery programs will enable the identification of novel therapeutics that target MIF functions in diseases with an inflammatory component. Furthermore, attention should be given to the MIF structural homolog  $\beta$ -DT, which has been demonstrated to have an overlapping functional spectrum of action. This suggests that the combined or separate therapeutic targeting of  $\beta$ -DT and MIF could have additional advantages.

### Conflicts of interest

The authors declare that they have no conflicts of interest.

### Acknowledgments

We thank the Directorate General of Higher Education Indonesia (DIKTI) for giving the grant 94.18/E4.4/2014, in collaboration with the University of Surabaya (Ubaya), Indonesia, and the University of Groningen, The Netherlands (to T.K). We acknowledge the European Research Council for providing ERC starting grant 309782 (to F.J.D.) and the NWO for providing VIDI grants 723.012.005 (to F.J.D.) and 700.56.421 (to G.J.P.).

### References

- 1 David, J.R. (1966) Delayed hypersensitivity *in vitro*: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. *Proc. Natl. Acad. Sci. U. S. A.* 56, 72–77
- 2 Bloom, B.R. and Bennett, B. (1966) Mechanism of a reaction *in vitro* associated with delayed-type hypersensitivity. *Science* 153, 80–82
- 3 Nathan, C.F. *et al.* (1971) Alterations of macrophage functions by mediators from lymphocytes. *J. Exp. Med.* 133, 1356–1376
- 4 Bloom, J. *et al.* (2016) MIF, a controversial cytokine: a review of structural features, challenges, and opportunities for drug development. *Expert Opin. Ther. Targets* 20, 1463–1475
- 5 Shen, D. *et al.* (2018) Roles of macrophage migration inhibitory factor in Guillain-Barré syndrome and experimental autoimmune neuritis: beneficial or harmful? *Expert Opin. Ther. Targets* <http://dx.doi.org/10.1080/14728222.2018.1484109> (in press)

- 6 Weiser, W.Y. *et al.* (1989) Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. *Proc. Natl. Acad. Sci. U. S. A.* 86, 7522–7526
- 7 Merk, M. *et al.* (2012) D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. *Cytokine* 59, 10–17
- 8 Poelarends, G.J. *et al.* (2008) The chemical versatility of the beta-alpha-beta fold: catalytic promiscuity and divergent evolution in the tautomerase superfamily. *Cell. Mol. Life Sci.* 65, 3606–3618
- 9 Wasiel, A.A. *et al.* (2010) Structural and functional characterization of a macrophage migration inhibitory factor homologue from the marine cyanobacterium *Prochlorococcus marinus*. *Biochemistry* 49, 7572–7581
- 10 Wasiel, A.A. *et al.* (2012) Dehalogenation of an anthropogenic compound by an engineered variant of the mouse cytokine macrophage migration inhibitory factor. *Chembiochem* 13, 1270–1273
- 11 Sparkes, A. *et al.* (2017) The non-mammalian MIF superfamily. *Immunobiology* 222, 473–482
- 12 Suzuki, M. *et al.* (1996) Crystal structure of the macrophage migration inhibitory factor from rat liver. *Nat. Struct. Biol.* 3, 259–266
- 13 Calandra, T. and Roger, T. (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. *Nat. Rev. Immunol.* 3, 791–800
- 14 Rosengren, E. *et al.* (1997) The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. *FEBS Lett.* 417, 85–88
- 15 Donnelly, S.C. and Bucala, R. (1997) Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. *Mol. Med. Today* 3, 502–507
- 16 Lubetsky, J.B. *et al.* (1999) Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. *Biochemistry* 38, 7346–7354
- 17 Cooke, G. *et al.* (2009) Macrophage migration inhibitory factor (MIF), enzymatic activity and the inflammatory response. *Biofactors* 35, 165–168
- 18 Leng, L. *et al.* (2003) MIF signal transduction initiated by binding to CD74. *J. Exp. Med.* 197, 1467–1476
- 19 Pantouris, G. *et al.* (2015) An analysis of MIF structural features that control functional activation of CD74. *Chem. Biol.* 22, 1197–1205
- 20 Su, H. *et al.* (2017) The biological function and significance of CD74 in immune diseases. *Inflamm. Res.* 66, 209–216
- 21 Merk, M. *et al.* (2011) The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). *Proc. Natl. Acad. Sci. U. S. A.* 108, E577–E585
- 22 Benedek, G. *et al.* (2017) MIF and D-DT are potential disease severity modifiers in male MS subjects. *Proc. Natl. Acad. Sci. U. S. A.* 114
- 23 O'Reilly, C. *et al.* (2016) Targeting MIF in cancer: therapeutic strategies, current developments, and future opportunities. *Med. Res. Rev.* 36, 440–460
- 24 Weber, C. *et al.* (2008) Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. *Proc. Natl. Acad. Sci. U. S. A.* 105, 16278–16283
- 25 Bernhagen, J. *et al.* (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. *Nat. Med.* 13, 587–596
- 26 Grieb, G. *et al.* (2015) MIF and CD74 – suitability as clinical biomarkers. *Mini Rev. Med. Chem.* 14, 1125–1131
- 27 Schindler, L. *et al.* (2018) Post-translational regulation of macrophage migration inhibitory factor: basis for functional fine-tuning. *Redox Biol.* 15, 135–142
- 28 Schinagel, A. *et al.* (2018) Role of the cysteine 81 residue of macrophage migration inhibitory factor as a molecular redox switch. *Biochemistry* 57, 1523–1532
- 29 Thiele, M. *et al.* (2015) Selective targeting of a disease-related conformational isoform of macrophage migration inhibitory factor ameliorates inflammatory conditions. *J. Immunol.* 195, 2343–2352
- 30 Schinagel, A. *et al.* (2016) Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer. *Oncotarget* 7, 73486–73496
- 31 Al-Abed, Y. and VanPatten, S. (2011) MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. *Future Med. Chem.* 3, 45–63
- 32 Bruchfeld, A. *et al.* (2016) Macrophage migration inhibitory factor in clinical kidney disease. *Front. Immunol.* 7, 8
- 33 Meyer-Siegler, K.L. and Vera, P.L. (2004) Intraluminal antibodies to macrophage migration inhibitory factor decrease substance P induced inflammatory changes in the rat bladder and prostate. *J. Urol.* 172, 1504–1509
- 34 Weiser, J.N. *et al.* (2015) Macrophage migration inhibitory factor is detrimental in pneumococcal pneumonia and a target for therapeutic immunomodulation. *J. Infect. Dis.* 212, 1677–1682
- 35 Russell, K.E. *et al.* (2016) The MIF antagonist ISO-1 attenuates corticosteroid-insensitive inflammation and airways hyperresponsiveness in an ozone-induced model of COPD. *PLoS One* 11, 1–17
- 36 Tynan, A. *et al.* (2017) Macrophage migration inhibitory factor enhances *Pseudomonas aeruginosa* biofilm formation, potentially contributing to cystic fibrosis pathogenesis. *FASEB J.* 31, 5102–5110
- 37 Savva, A. *et al.* (2016) Functional polymorphisms of macrophage migration inhibitory factor as predictors of morbidity and mortality of pneumococcal meningitis. *Proc. Natl. Acad. Sci. U. S. A.* 113, 3597–3602
- 38 Matsui, Y. *et al.* (2004) Blockade of macrophage migration inhibitory factor ameliorates experimental autoimmune myocarditis. *J. Mol. Cell. Cardiol.* 37, 557–566
- 39 Mikulowska, A. *et al.* (1997) Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. *J. Immunol.* 158, 5514–5517
- 40 Nobre, C.C.G. *et al.* (2017) Macrophage migration inhibitory factor (MIF): biological activities and relation with cancer. *Pathol. Oncol. Res.* 23, 235–244
- 41 Kindt, N. *et al.* (2016) Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets. *Oncol. Lett.* 12, 2247–2253
- 42 Meyer-Siegler, K.L. *et al.* (2006) Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. *J. Immunol.* 177, 8730–8739
- 43 Hussain, F. *et al.* (2013) Human anti-macrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells *in vitro* and *in vivo*. *Mol. Cancer Ther.* 12, 1223–1234
- 44 Choudhary, S. *et al.* (2013) Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. *Carcinogenesis* 34, 2891–2899
- 45 He, X.-X. *et al.* (2009) Macrophage migration inhibitory factor promotes colorectal cancer. *Mol. Med.* 15, 1–10
- 46 Mawhinney, L. *et al.* (2014) Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer. *Mol. Med.* 20, 729–735
- 47 Mangano, K. *et al.* (2018) Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. *Oncotarget* 9, 17951–17970
- 48 Lechien, J.R. *et al.* (2017) Role of macrophage migration inhibitory factor in head and neck cancer and novel therapeutic targets: a systematic review. *Head Neck* 39, 2573–2584
- 49 Wang, S. *et al.* (2017) Macrophage migration inhibitory factor: a potential driver and biomarker for head and neck squamous cell carcinoma. *Oncotarget* 8, 10650–10661
- 50 Phase I Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors. Available at: <https://clinicaltrials.gov/ct2/show/study/NCT01765790>
- 51 Orita, M. *et al.* (2001) Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography. *J. Med. Chem.* 44, 540–547
- 52 Cisneros, J.A. *et al.* (2016) Irregularities in enzyme assays: the case of macrophage migration inhibitory factor. *Bioorg. Med. Chem. Lett.* 26, 2764–2767
- 53 Lubetsky, J.B. *et al.* (2002) The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. *J. Biol. Chem.* 277, 24976–24982
- 54 Cournia, Z. *et al.* (2009) Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. *J. Med. Chem.* 52, 416–424
- 55 Tanese, K. *et al.* (2015) Cell surface CD74-MIF interactions drive melanoma survival in response to interferon- $\gamma$ . *J. Invest. Dermatol.* 135, 2775–2784
- 56 Korf, H. *et al.* (2017) MIF inhibition interferes with the inflammatory and T cell-stimulatory capacity of NOD macrophages and delays autoimmune diabetes onset. *PLoS One* 12, e0187455
- 57 Kithcart, A.P. *et al.* (2010) A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. *FASEB J.* 24, 4459–4466
- 58 Alam, A. *et al.* (2011) Synthesis and bio-evaluation of human macrophage migration inhibitory factor inhibitor to develop anti-inflammatory agent. *Bioorg. Med. Chem.* 19, 7365–7373
- 59 Ioannou, K. *et al.* (2014) ISO-66, a novel inhibitor of macrophage migration, shows efficacy in melanoma and colon cancer models. *Int. J. Oncol.* 45, 1457–1468
- 60 Jorgensen, W.L. *et al.* (2010) Receptor agonists of macrophage migration inhibitory factor. *Bioorg. Med. Chem. Lett.* 20, 7033–7036
- 61 Dziedzic, P. *et al.* (2015) Design, synthesis, and protein crystallography of biaryltriazoles as potent tautomerase inhibitors of macrophage migration inhibitory factor. *J. Am. Chem. Soc.* 137, 2996–3003
- 62 Cisneros, J.A. *et al.* (2016) A fluorescence polarization assay for binding to macrophage migration inhibitory factor and crystal structures for complexes of two potent inhibitors. *J. Am. Chem. Soc.* 138, 8630–8638
- 63 Winner, M. *et al.* (2008) A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. *Cancer Res.* 68, 7253–7257
- 64 Varinelli, L. *et al.* (2015) 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas. *Endocr. Relat. Cancer* 22, 759–775



- 65 Ouertatani-Sakouhi, H. *et al.* (2009) A new class of isothiocyanate-based irreversible inhibitors of macrophage migration inhibitory factor. *Biochemistry* 48, 9858–9870
- 66 Woodward, R.B. *et al.* (1961) A new synthesis of peptides. *J. Am. Chem. Soc.* 83, 1010–1012
- 67 Woodward, R.B. and Olofson, R.A. (1961) The reaction of isoxazolium salts with bases. *J. Am. Chem. Soc.* 83, 1007–1009
- 68 Qian, Y. *et al.* (2016) Activity-based proteome profiling probes based on Woodward's reagent K with distinct target selectivity. *Angew. Chem. Int. Ed.* 55, 7766–7771
- 69 Bilich, A. *et al.* (2018) Preparation of 3,4-dihydrobenzo[e][1,3]oxazin-2-ones as mediators of macrophage migration inhibitory factor (MIF). Novartis Ag, Novartis Pharma GmbH WO 2006108671
- 70 Hare, A.A. *et al.* (2010) Optimization of *N*-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). *Bioorg. Med. Chem. Lett.* 20, 5811–5814
- 71 Bai, F. *et al.* (2012) A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF). *J. Biol. Chem.* 287, 30653–30663
- 72 Bloom, J. *et al.* (2016) Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential. *J. Biol. Chem.* 291, 26502–26514
- 73 Vujicic, M. *et al.* (2014) Novel inhibitors of macrophage migration inhibitory factor prevent cytokine-induced beta cell death. *Eur. J. Pharmacol.* 740, 683–689
- 74 Kok, T. *et al.* (2017) Discovery of chromenes as inhibitors of macrophage migration inhibitory factor. *Bioorg. Med. Chem.* 26, 999–1005
- 75 Strelow, J. *et al.* (2004) Mechanism of action assays for enzymes. *Transl. Sci.* PMID: 22553872



# DRUG DISCOVERY TODAY

Authoritative reviews and expert opinion  
Industry focused, peer reviewed

- The development of fragment-based drug discovery
- Retinal pigment epithelial cells as therapeutic targets
- Role of lncRNAs in ovarian cancer
- Interrogating the microbiome

September 2018 Volume 23 No. 9/12

[www.drugdiscoverytoday.com](http://www.drugdiscoverytoday.com)



Supports Open Access

View Articles

Guide for Authors



Abstracting/ Indexing

Track Your Paper

Order Journal



Journal Metrics

CiteScore: 5.76

More about CiteScore

Impact Factor: 6.848

5-Year Impact Factor: 6.536

Source Normalized Impact per Paper (SNIP): 1.518

SCImago Journal Rank (SJR): 2.008

Your Research Data

> Share your research data

# Drug Discovery Today - Editorial Board

---

## Editor

Stephen Carney

---

## Advisory Editorial Board

Jürgen Bajorath

Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany

David Brayden

University College Dublin, Dublin, Ireland

Paul Caron

Vertex Pharmaceuticals Inc, Cambridge, Massachusetts, USA

David Cavalla

Numedicus Limited, Cambridge, England, UK

David Clark

Argenta Discovery Ltd., Harlow, UK

---



ISSN: 1359-6446

Supports Open Access

View Articles

Guide for Authors



Abstracting/ Indexing

# Drug Discovery Today

Editor: Stephen Carney

> View Editorial Board

*Drug Discovery Today* delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in **drug discovery** associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D...

Read more

Most Downloaded Articles



Feedback



## Volume 23, Issue 11

Pages 1807-1918 (November 2018)

[Download full issue](#)

[< Previous vol/issue](#)

[Next vol/issue >](#)

Full text access

### Contents page 1

Page i

[View PDF](#)

Full text access

### Contents page 2

Page ii

[View PDF](#)

### *Editorial*

Editorial  No access

#### Is the independence of medical research at stake? On the forces shaping the research agenda

Deanna Anderlini

Pages 1807-1808

Editorial  No access

#### Biobanks: let's share specimens

Christopher J. Ianelli

Pages 1809-1811

[Submit your article](#)

[Guide for authors](#)

Menu



---

## Translational strategy: humanized mini-organs

Duong T. Nguyen, Magnus Althage, Maria Chiara Magnone, Sepideh Heydarkhan-Hagvall  
Pages 1812-1817

[Article preview](#) ✓

Mini review  Abstract only

## Why breast cancer signatures are no better than random signatures explained

Wilson Wen Bin Goh, Limsoon Wong  
Pages 1818-1823

[Article preview](#) ✓

---

## REVIEWS

---

### Keynote

Review article  *Open access*

## Recommendations toward a human pathway-based approach to disease research

Lindsay J. Marshall, Christopher P. Austin, Warren Casey, Suzanne C. Fitzpatrick, Catherine Willett  
Pages 1824-1832



[View PDF](#)

[Article preview](#) ✓

Review article  Abstract only

## The A-Z of Zika drug discovery

Melina Mottin, Joyce V.V.B. Borba, Rodolpho C. Braga, Pedro H.M. Torres, ... Carolina Horta Andrade  
Pages 1833-1847

[Article preview](#) ✓

Review article  Abstract only

## Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology

Demosthenes E. Ziogas, Ioannis D. Kyrochristos, Dimitrios H. Roukos  
Pages 1848-1872

[Article preview](#) ✓

---

### Gene to Screen

Review article  Abstract only

[Submit your article](#)

[Guide for authors](#)

Menu



[Review article](#)  [Abstract only](#)

## Mapping genes for drug chronotherapy

Kun Wei, Qian Wang, Jingwen Gan, Shilong Zhang, ... Rongling Wu

Pages 1883-1888

[Article preview](#)

### *Informatics*

---

[Review article](#)  [Abstract only](#)

## Selection of protein conformations for structure-based polypharmacology studies

Luca Pinzi, Fabiana Caporuscio, Giulio Rastelli

Pages 1889-1896

[Article preview](#)

### *Post Screen*

---

[Review article](#)  [Abstract only](#)

## Delivery systems of local anesthetics in bone surgery: are they efficient and safe?

Manon Dupleichs, Qiman Gao, Zahi Badran, Pascal Janvier, ... Elise Verron

Pages 1897-1903

[Article preview](#)

[Review article](#)  [Abstract only](#)

## Why are there no drugs indicated for sciatica, the most common chronic neuropathic syndrome of all?

John D. Markman, Ralf Baron, Jennifer S. Gewandter

Pages 1904-1909

[Article preview](#)

[Review article](#)  [Abstract only](#)

## Small-molecule inhibitors of macrophage migration inhibitory factor (MIF) as an emerging class of therapeutics for immune disorders

Tjie Kok, Anna A. Wasiel, Robbert H. Cool, Barbro N. Melgert, ... Frank J. Dekker

Pages 1910-1918

[Article preview](#)

# Drug Discovery Today

Supports *open access*



[Submit your article](#)

[Guide for authors](#)

Menu




Copyright © 2023 Elsevier B.V. or its licensors or contributors.  
ScienceDirect® is a registered trademark of Elsevier B.V.



FEEDBACK



## Drug Discovery Today

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
<a href="#">United Kingdom</a>  	<a href="#">Pharmacology, Toxicology and Pharmaceutics</a> <a href="#">Drug Discovery</a> <a href="#">Pharmacology</a>	<a href="#">Elsevier Ltd.</a>	<b>195</b>
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
<a href="#">Journals</a>	18785832, 13596446	1996-2022	<a href="#">Homepage</a> <a href="#">How to publish in this journal</a> <a href="mailto:DDT@drugdiscoverytoday.com">DDT@drugdiscoverytoday.com</a>

### SCOPE

Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports. Coverage includes: • Novel therapeutic strategies • High-throughput screening • Therapeutic targets • Combinatorial chemistry, parallel synthesis and library design • Drug delivery • ADME/Tox • Advances in key compound classes and therapeutic areas • Genomics and proteomics • Automation and technology • Virtual chemistry • Informatics • Business strategy • Clinical trials and other aspects of drug discovery.

 [Join the conversation about this journal](#)

FIND SIMILAR JOURNALS ?

options :

1  
Expert Opinion on Drug  
Discovery  
GBR

2  
Current Medicinal Chemistry  
ARE

3  
Current Drug Targets  
ARE

4  
Pharmaceuticals  
CHE

5  
Current Topics in Medicinal  
Chemistry  
ARE

69%  
similarity

67%  
similarity

65%  
similarity

64%  
similarity

62%  
similarity



**Drug Discovery Today**

Q1 Drug Discovery  
best quartile

SJR 2022  
1.4

powered by scimagojr.com

← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com" style="display: inline-block; width: 100px; height: 15px; background-color: #f0f0f0; border: 1px solid #ccc;">
```

**SCImago Graphica**

Explore, visually communicate and make sense of data with our [new data visualization tool](#).



Metrics based on Scopus® data as of April 2023

**Leave a comment**

Name

Email

(will not be published)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS  
© Scopus, Scopus, S.I., 1996

[Cookie settings](#)

[Cookie policy](#)

---



# Source details

## Drug Discovery Today

Incorporating: Pharmaceutical Science and Technology Today

Incorporating: Drug Discovery Today: BIOSILICO

Incorporating: Drug Discovery Today: TARGETS

Scopus coverage years: from 1996 to Present

Publisher: Elsevier

ISSN: 1359-6446 E-ISSN: 1878-5832

Subject area: [Pharmacology, Toxicology and Pharmaceutics: Pharmacology](#)

[Pharmacology, Toxicology and Pharmaceutics: Drug Discovery](#)

Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

CiteScore 2022

14.7



SJR 2022

1.397



SNIP 2022

1.663



[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

CiteScore 2022

$$14.7 = \frac{12,536 \text{ Citations 2019 - 2022}}{853 \text{ Documents 2019 - 2022}}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023

$$11.6 = \frac{8,998 \text{ Citations to date}}{773 \text{ Documents to date}}$$

Last updated on 07 June, 2023 • Updated monthly

### CiteScore rank 2022

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#15/301	95th
└ Pharmacology		
Pharmacology, Toxicology and Pharmaceutics	#11/156	93rd
└ Drug Discovery		

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

---

## About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

## Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

## Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

---

## ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. ↗ . All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.

